Oral sophocarpine protects rat heart against pressure overload-induced cardiac fibrosis

References

• Chen SX, Hang YN, Zhang MZ, et al. (2005). Hemodynamic study of sophocarpine in dogs. Chinese J Integr Med Cardio/Cerebrovascular Dis 10:875–7
   Google Scholar
• Cleutjens JP, Verluyten MJ, Smiths JF, Daemen MJ. (1995). Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol 147:325–38
   PubMed Web of Science ®Google Scholar
• de Jong S, van Veen TA, de Bakker JM, van Rijen HV. (2012). Monitoring cardiac fibrosis: A technical challenge. Neth Heart J 20:44–8
   PubMedGoogle Scholar
• Ferreira AJ, Shenoy V, Qi Y, et al. (2011). Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol 96:287–94
   PubMed Web of Science ®Google Scholar
• Gao YL, Li GS, Li CM, et al. (2009). Anti-nociceptive and anti-inflammatory activity of sophocarpine. J Ethnopharmacol 125:324–9
   PubMed Web of Science ®Google Scholar
• Gu Y, Wang X, Wang X, et al. (2012). Artemisinin attenuates post-infarct myocardial remodeling by down-regulating the NF-κB pathway. Tohoku J Exp Med 227:161–70
   PubMed Web of Science ®Google Scholar
• Gullestad L, Aukrust P. (2005). Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. Am J Cardiol 95:17–23C; discussion 38–40C
   Google Scholar
• Hao J, Kim CH, Ha TS, Ahn HY. (2007). Epigallocatechin-3 gallate prevents cardiac hypertrophy induced by pressure overload in rats. J Vet Sci 8:121–9
   PubMedGoogle Scholar
• Israf DA, Khaizurin TA, Lajis NH, Khozirah S. (2007). Cardamonin inhibits COX and iNOS expression via inhibition of p65NF-κB nuclear translocation and Iκ-B phosphorylation in RAW264.7 macrophage cells. Mol Immunol 44:673–9
   PubMed Web of Science ®Google Scholar
• Kudo H, Kai H, Kajimoto H, et al. (2009). Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation. Hypertension 54:832–8
   PubMed Web of Science ®Google Scholar
• Kuusisto J, Kärjä V, Sipola P, et al. (2012). Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy. Heart 98:1007–13
   PubMed Web of Science ®Google Scholar
• Kuwahara F, Kai H, Tokuda K, et al. (2004). Hypertensive myocardial fibrosis and diastolic dysfunction: Another model of inflammation? Hypertension 43:739–45
   PubMed Web of Science ®Google Scholar
• Levick SP, McLarty JL, Murray DB, et al. (2009). Cardiac mast cells mediate left ventricular fibrosis in the hypertensive rat heart. Hypertension 53:1041–7
   PubMed Web of Science ®Google Scholar
• Levick SP, Murray DB, Janicki JS, Brower GL. (2010). Sympathetic nervous system modulation of inflammation and remodeling in the hypertensive heart. Hypertension 55:270–6
   PubMed Web of Science ®Google Scholar
• Li C, Gao Y, Tian J, et al. (2011). Sophocarpine administration preserves myocardial function from ischemia-reperfusion in rats via NF-κB inactivation. J Ethnopharmacol 135:620–5
   PubMed Web of Science ®Google Scholar
• López B, González A, Díez J. (2004). Role of matrix metalloproteinases in hypertension-associated cardiac fibrosis. Curr Opin Nephrol Hypertens 13:197–204
   PubMed Web of Science ®Google Scholar
• Nian M, Lee P, Khaper N, Liu P. (2004). Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 94:1543–53
   PubMed Web of Science ®Google Scholar
• Sakamoto A, Hongo M, Furuta K, et al. (2013). Pioglitazone ameliorates systolic and diastolic cardiac dysfunction in rat model of angiotensin II-induced hypertension. Int J Cardiol 167:409–15
   PubMedGoogle Scholar
• Shibata R, Izumiya Y, Sato K, et al. (2007). Adiponectin protects against the development of systolic dysfunction following myocardial infarction. J Mol Cell Cardiol 42:1065–74
   PubMed Web of Science ®Google Scholar
• Taqueti VR, Mitchell RN, Lichtman AH. (2006). Protecting the pump: Controlling myocardial inflammatory responses. Annu Rev Physiol 68:67–95
   PubMedGoogle Scholar
• Tschöpe C, Walther T, Königer J, et al. (2004). Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. FASEB J 18:828–35
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Carini G, Circo A, et al.; MAVI (MAssa Ventricolare sinistra nell'Ipertensione) Study Group. (2001). Left ventricular mass and cardiovascular morbidity in essential hypertension: The MAVI study. J Am Coll Cardiol 38:1829–35
   PubMed Web of Science ®Google Scholar
• Weber KT. (2004). From inflammation to fibrosis: A stiff stretch of highway. Hypertension 43:716–19
   PubMed Web of Science ®Google Scholar
• Xiao P, Kubo H, Komiya H, et al. (1999). Lupin alkaloids from seeds of Sophora viccifolia. Phytochemistry 50:189–93
   Google Scholar
• Yasuda S, Miyazaki S, Kinoshita H, et al. (2007). Enhanced cardiac production of matrix metalloproteinase-2 and -9 and its attenuation associated with pravastatin treatment in patients with acute myocardial infarction. Clin Sci (Lond) 112:43–9
   PubMedGoogle Scholar
• Yu XJ, He ZY, Wang XY. (2004). Dynamic changes of myocardial fibrosis in two hypertensive models of rats and the relationship between pressure overload and RAS. J Chin Microcircul 8:209–13
   Google Scholar
• Zhang Y, Wang S, Li Y, et al. (2008). Sophocarpine and matrine inhibit the production of TNF and IL-6 in murine macrophages and prevent cachexia-related symptoms induced by colon 26 adenocarcinoma in mice. Int Immunopharmacol 8:1767–72
   PubMed Web of Science ®Google Scholar
• Zhao LJ, Jiao DD, Zhao ZM. (2009). The establishment of rat myocardial fibrosis model by abdominal aortic banding. J Chin Microcircul 13:402–4
   Google Scholar